Revalesio Unveils Promising Results from Phase 2 RESCUE Trial
Revalesio has made significant strides in stroke treatment with their recent analyses from the Phase 2 RESCUE trial of RNS60, aimed at patients suffering from acute ischemic stroke (AIS). This groundbreaking research highlights a remarkable 50% reduction in infarct growth, or brain tissue loss, for patients treated within a critical time frame of 12 hours from their last known well state.
Notably, this reduction in infarct growth corresponded with substantial improvements in various functional stroke measures crucial for assessing patient recovery, laying the foundation for future treatment strategies.
Key Findings from the RESCUE Study
During an oral presentation at a prestigious international conference, Revalesio’s team discussed their findings, which underscored the efficacy of RNS60 as a promising treatment for AIS. The trial involved 82 participants who were eligible for endovascular thrombectomy (EVT) and who received either RNS60 or placebo. The team conducted a thorough analysis to evaluate both safety and initial efficacy.
The results were compelling. The high dose of RNS60 not only significantly reduced infarct growth but also showed numerically better performance in each prespecified functional endpoint, including:
- Modified Rankin Score (mRS): 72% of participants receiving the high dose of RNS60 became independent by Day 90, compared to just 37% on placebo.
- Barthel Index (BI): An impressive 72% of those on RNS60 returned to normal daily activities at Day 90 versus 37% on placebo.
- Patient Health Status: Scores improved significantly, with RNS60 subjects averaging an EQ-5D-5L Index of 0.79 compared to 0.57 for those on placebo.
Furthermore, RNS60 was well tolerated, with no significant safety concerns raised during the trial.
Potential Impact of RNS60 on Stroke Treatment
Stroke remains one of the leading causes of global disability, and the statistics are troubling. Each year, the economic impact related to stroke is about $721 billion worldwide—an urgent call for effective therapies. RNS60's promising results reflect an essential step forward in addressing this critical healthcare need.
Insights from Medical Experts
Dr. Marc Fisher, a neurologist affiliated with Harvard Medical School, emphasized the importance of these findings. He highlighted that the results suggest RNS60 has the potential to significantly impact the way AIS is treated, warranting further investigation in a large-scale Phase 3 clinical trial.
Bert van den Bergh, Revalesio's Executive Chairman, echoed this sentiment. He pointed out that with more than 80% of stroke patients in the U.S. left with limited treatment options, RNS60 could transform future therapeutic strategies. The ongoing commitment to advance RNS60 into comprehensive clinical studies reflects Revalesio's dedication to enhancing patient outcomes post-stroke.
Understanding RNS60
RNS60 is an innovative investigational therapy designed to target the underlying mechanisms in neurological conditions. The research indicates its ability to activate vital intracellular pathways, promoting neuronal health and recovery. In addition to stroke, Revalesio has plans to explore RNS60 in conditions like ALS and other neurological disorders, broadening its potential horizons.
About Revalesio
Revalesio is a pioneering clinical-stage pharmaceutical company committed to reshaping treatment strategies for acute and chronic neurological disorders. Their dedication to research and development is evident in their approach to addressing the root causes of cellular dysfunction. With a focus on improving quality of life for patients, Revalesio is well-positioned to lead advancements in this vital area of medicine.
Frequently Asked Questions
What were the main findings from the RESCUE trial?
The RESCUE trial found that RNS60 significantly reduced infarct growth by 50% in patients treated within 12 hours, correlating with improved functional outcomes.
What is RNS60?
RNS60 is an investigational therapeutic aimed at modifying diseases of the nervous system, promoting neuronal health and reducing inflammation.
How does this research impact stroke treatment?
This research suggests that RNS60 can be a game changer for AIS treatment, especially since many patients currently lack effective therapeutic options.
What future studies are planned for RNS60?
Revalesio plans to initiate a Phase 3 clinical trial to further evaluate the efficacy and safety of RNS60 in stroke patients.
Who presented the findings at the conference?
The findings were presented by Jordan Dubow, M.D., Acting Chief Medical Officer of Revalesio, during an oral session at the conference.
